BioSpace

Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027

Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented data this week showing its clinically meaningful benefit in older patients who are able to walk.

Par BioSpace

1 minute de lecture
Partager
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027

Vous avez une actualité à partager avec le secteur événementiel ?

Envoyez un communiqué de presse ou une information et touchez des milliers de professionnels de l'événementiel.

Nous contacter→

Plus dans Health Tech

Articles connexes